1. Heald RJ, Ryall RDH. Recurence and survival after total mesorectal excision for rectal cancer. Lancet. 1986;1479–82.
2. MacFarlane JK, Ryall RD, Heald RJ. Mesorectal excision for rectal cancer. Lancet (London, England) [Internet]. 1993 Feb 20;341(8843):457–60. Available from: http://www.ncbi.nlm.nih.gov/pubmed/8094488
3. Lacy AM, Fuerst A, Haglind E, van der Pas MHGM, Cuesta MA, Rosenberg J, et al. A Randomized Trial of Laparoscopic versus Open Surgery for Rectal Cancer. N Engl J Med. 2015;372(14):1324–32.
4. Eveno C, Lamblin A, Mariette C, Pocard M. Sexual and urinary dysfunction after proctectomy for rectal cancer. J Visc Surg. 2010;147(1).
5. Chorost MI, Weber TK, Lee RJ, Rodriguez-Bigas MA, Petrelli NJ. Sexual dysfunction, informed consent and multimodality therapy for rectal cancer. Am J Surg [Internet]. 2000 Apr;179(4):271–4. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0002961000003275
6. Leon-Carlyle M, Schmocker S, Victor JC, Maier BA, O’Connor BI, Baxter NN, et al. Prevalence of Physiologic Sexual Dysfunction Is High Following Treatment for Rectal Cancer: But Is It the Only Thing That Matters? Dis Colon Rectum. 2015;58(8):736–42.
7. Sanoff HK, Morris WL, Mitcheltree AL, Wilson S, Lund JL. Lack of support and information regarding long-term negative effects in survivors of rectal cancer. Clin J Oncol Nurs [Internet]. 2015 Aug 1;19(4):444–8. Available from: http://cjon.ons.org/cjon/19/4/lack-support-and-information-regarding-long-term- negative-effects-survivors-rectal-cancer
8. Celentano V, Cohen R, Warusavitarne J, Faiz O, Chand M. Sexual dysfunction following rectal cancer surgery. Int J Colorectal Dis. 2017;32(11):1523–30.
9. Ho VP, Lee Y, Stein SL, Temple LKF. Sexual function after treatment for rectal cancer: A review. Dis Colon Rectum. 2011;54(1):113–25.
10. Kim HJ, Choi GS, Park JS, Park SY, Yang CS, Lee HJ. The impact of robotic surgery on quality of life, urinary and sexual function following total mesorectal excision for rectal cancer: a propensity score-matched analysis with laparoscopic surgery. Color Dis. 2018;20(5):O103–13.
11. Toda S, Kuroyanagi H. Laparoscopic surgery for rectal cancer: Current status and future perspective. Asian J Endosc Surg [Internet]. 2014 Jan;7(1):2–10. Available from: http://doi.wiley.com/10.1111/ases.12074
12. Dulskas A, Samalavicius NE. A prospective study of sexual and urinary function before and after total mesorectal excision. Int J Colorectal Dis [Internet]. 2016;31(6):1125–30. Available from: http://dx.doi.org/10.1007/s00384-016- 2549-y
13. Attaallah W, Ertekin SC, Yegen C. Prospective study of sexual dysfunction after proctectomy for rectal cancer. Asian J Surg [Internet]. 2018;41(5):454–61. Available from: https://doi.org/10.1016/j.asjsur.2017.04.005
14. Adam J-P, Denost Q, Capdepont M, van Geluwe B, Rullier E. Prospective and Longitudinal Study of Urogenital Dysfunction After Proctectomy for Rectal Cancer. Dis Colon Rectum [Internet]. 2016 Sep;59(9):822–30. Available from: http://insights.ovid.com/crossref?an=00003453-201609000-00003
15. Koedam TWA, van Ramshorst GH, Deijen CL, Elfrink AKE, Meijerink WJHJ, Bonjer HJ, et al. Transanal total mesorectal excision (TaTME) for rectal cancer: effects on patient-reported quality of life and functional outcome. Tech Coloproctol. 2017;21(1):25–33.
16. Engel J, Kerr J, Schlesinger-Raab A, Eckel R, Sauer H, Hölzel D. Quality of Life in Rectal Cancer Patients. Ann Surg [Internet]. 2003 Aug;238(2):203–13. Available from: https://insights.ovid.com/crossref?an=00000658-200308000-00008
17. Andersson J, Abis G, Gellerstedt M, Angenete E, Cuesta MA, Jess P, et al. Patient-reported genitourinary dysfunction after laparoscopic and open rectal cancer surgery in a randomized trial (COLOR II). Br J Surg. 2014;101(10):1272– 9.
18. Jayne D, Pigazzi A, Marshall H, Croft J, Corrigan N, Copeland J, et al. Effect of robotic-assisted vs conventional laparoscopic surgery on risk of conversion to open laparotomy among patients undergoing resection for rectal cancer the rolarr randomized clinical trial. JAMA [Internet]. 2017 Oct 24;318(16):1569. Available from: http://jama.jamanetwork.com/article.aspx?doi=10.1001/jama.2017.7219
19. Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A. The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology [Internet]. 1997 Jun;49(6):822–30. Available from: http://www.ncbi.nlm.nih.gov/pubmed/9187685
20. Barry MJ, Fowler FJ, O’Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK, et al. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol [Internet]. 1992 Nov;148(5):1549–57; discussion 1564. Available from: http://www.ncbi.nlm.nih.gov/pubmed/1279218
21. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst [Internet]. 1993 Mar 3;85(5):365–76. Available from: http://www.ncbi.nlm.nih.gov/pubmed/8433390
22. Rubin DB. Multiple imputation for nonresponse in surveys Donald B. Rubin. Wiley Series in Probability and Statistics. 1987.
23. Hida K, Hasegawa S, Kataoka Y, Nagayama S, Yoshimura K, Nomura A, et al. Male sexual function after laparoscopic total mesorectal excision. Color Dis. 2013;15(2):244–51.
24. Kim NK, Aahn TW, Park JK, Lee KY, Lee WH, Sohn SK, et al. Assessment of Sexual and Voiding Function After Total Mesorectal Excision With Pelvic Autonomic Nerve Preservation in Males With Rectal Cancer. Dis Colon Rectum [Internet]. 2002 Sep;45(9):1178–85. Available from: https://insights.ovid.com/crossref?an=00003453-200245090-00005
25. Hendren SK, O’Connor BI, Liu M, Asano T, Cohen Z, Swallow CJ, et al. Prevalence of male and female sexual dysfunction is high following surgery for rectal cancer. Ann Surg. 2005;242(2):212–23.
26. Schmidt CE, Bestmann B, Küchler T, Longo WE, Kremer B. Ten-Year Historic Cohort of Quality of Life and Sexuality in Patients With Rectal Cancer. Dis Colon Rectum [Internet]. 2005 Mar;48(3):483–92. Available from: https://insights.ovid.com/crossref?an=00003453-200548030-00011
27. Stefansson M, Nygren P. Oxaliplatin added to fluoropyrimidine for adjuvant treatment of colorectal cancer is associated with long-term impairment of peripheral nerve sensory function and quality of life. Acta Oncol (Madr). 2016;55(9–10):1227–35.
28. National Research Council (US) Panel on Handling Missing Data in Clinical Trials. The Prevention and Treatment of Missing Data in Clinical Trials. 2010.